Reaction Biology Corp. (RBC) was founded to pursue the economies
provided by new technologies in high throughput screening and
biochemical assays. RBC's technology advantage is derived from its
expertise in developing new nanoliter scale assaying methods.
By carefully scaling down enzyme and compound volume, RBC is able to offer
outsourced biochemical assays at a much more economical price than other
outsource or even in-house labs. Its Kinase HotSpot assay has created a
new niche in pharma selectivity screening.
RBC also performs NIH-funded research in technology development and
early stage drug discovery. Screening partnerships with industry
partners are also part of the RBC portfolio.
